Clinical Outcomes of Femtosecond Laser-assisted Pterygium... | NCT02866968

NCT02866968

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Status Module

Oversight Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Label	Type	Description	Intervention Names
Femtosecond Laser-assisted Pterygium Surgery (FLAPS)	Experimental	All patients included will undergo FLAPS in one eye.	Procedure: FLAPS

Interventions

Name	Type	Description	Arm Group Labels	Other Names
FLAPS	Procedure	Surgical procedures will involve 1) excision of pterygium tissue from cornea and conjunctiva, 2) resection of residual Tenon and coagulation to stop any bleeding 3) preparation of a 8x8 mm conjunctiva autograft in the superior bulbar conjunctiva with the femtosecond laser (12 o´clock position) and 4) fixation of the graft with fibrin glue to the resection site.

Outcomes Module

Measure	Description	Time Frame
Safety and Tolerability of FLAPS	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	12 month follow-up

Secondary Outcomes

Measure	Description	Time Frame
Recurrence free survival over 12 months.	Number of cases with pterygium recurrence during 12 month follow-up	12 month follow-up
Visual acuity	Best-spectacle corrected visual acuity (BSCVA) to be measured with a Snellen chart at 6 meters, then converted to logarithmic minimum angle of resolution unit to allow for averaging and statistical analysis

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

A pterygium will be defined as a wing-shaped growth of fibrotic connective tissue onto the cornea originating from the nasal conjunctiva.
Only patients older than 21 years will be included.
No gender criteria are applied.
Only individuals with the mental capacity to provide informed consent will be included.

More specifically, all the following inclusion criteria must be met:

Patients have primary pterygium encroaching onto the cornea by a minimum of 1 mm.
Patients are willing and able to sign a written Informed Consent Form prior to any study-specific procedures.
Patients are willing and able to return for scheduled follow-up examinations for 12 months after the surgery.

Exclusion Criteria:

Patients with prior history of pterygium surgery.
Patients with a prior history of glaucoma filtration surgery.
Patients with optic atrophy.
Patients with ocular pathology or disease that might confound the outcome or increase the risk of adverse events.
Patients with a prior history of vitrectomy.
Patients with central corneal scarring.
Patients with residual, recurrent, active or uncontrolled eyelid disease.
Patients with any conjunctival scarring other than pterygium, that could affect surgery outcome.
Patients with anterior segment pathology.
Patients with any corneal abnormality.
Patients with any progressive retinal disease or subjects with a history or evidence of retinal vascular occlusion and/or hypercoagulability, because of the risks associated with high pressures during suction application.
Patients with amblyopia or strabismus or those who are at risk for developing strabismus postoperatively as determined by corneal light reflex and cover-uncover testing.
Patients who are pregnant, lactating, of child-bearing potential and not practising a medically approved method of birth control, or planning to become pregnant during the course of the trial, and patients with other conditions associated with fluctuation of hormones that could lead to refractive changes.

ID	Term
D003229	Conjunctival Diseases
D005128	Eye Diseases